-
Japan Olympic chief says 'lot more' athletes at Games than expected
-
North Korea fires ballistic missile after Seoul's apology demand
-
Asian carmakers besting US rivals at home, China poised to strike
-
US regulator finds Boeing 737 MAX software bug 'not a safety concern'
-
Widgets & Web Offers All-Inclusive Investor Relations Websites for Public Companies, IPOs and SPACs
-
Ohtani 'managing' injuries as Dodgers launch MLB post-season
-
Adams named new US captain to 2030 World Cup
-
Botched US execution leaves murderer unconscious on ventilator: lawyers
-
China a better influence in Latin America than US: poll
-
Cornell rape case exposes sexual violence at US colleges
-
Judge pauses construction of border project in Texas national park
-
France held by Italy in Zidane's homecoming after Olise stunner
-
Belgium's De Bruyne fires double to sink Turkey, France held by Italy
-
Ethiopian pro-government militia claims Tigray airport as regional tensions spike
-
US jobs data boosts stocks as oil prices dip
-
Ohtani shaking off injuries as Dodgers launch MLB post-season
-
US Supreme Court to hear high-stakes climate case
-
Sea levels to rise in California as coastal wave surges up west coast
-
Trump expected to name intel chief Clayton as AI czar: reports
-
New rallies urged in France as protests disrupt over 730 schools
-
Argentina unveils passports-for-investment scheme
-
Djokovic survives China Open scare, Sabalenka starts strong
-
Brazil election debate chaos sparks censorship row
-
King Charles to evoke colonial 'darkest days' on Caribbean tour
-
England's Carse charged by cricket body over nightclub incident
-
Tesla shares jump after global car sales top estimates
-
Amazon vows $1 bn for data center towns, decries 'myths'
-
DR Congo Ebola outbreak killed more than 4,000: official figures
-
Oil prices drop on G7 fuel release, US jobs data boosts stocks
-
Djokovic survives China Open scare against wildcard world no. 104
-
G7 agrees deal to ease global energy supply concerns
-
Lula, Bolsonaro trade blows in final scramble for votes in Brazil
-
Spain's government dealt blow as lawmakers reject housing bills
-
New clashes erupt as protests disrupt over 560 French schools
-
Food, medicine shortages deepen in Russian-occupied Oleshky
-
NY governor vows to close loophole after alleged Cornell gang rape
-
Man City whistleblower Rui Pinto facing 'dire consequences' - lawyers
-
Ethiopia Tigray rebels pushed back as regional tensions spike
-
Russia 'tearing Kyiv apart', mayor says, as strikes paralyse traffic
-
Stocks rise, yields fall as US job numbers disappoint
-
Taiwan boxer Lin wins Games gold as Japan edge North Korea on penalties
-
Man City verdict a 'big topic' for England players, says Tuchel
-
Japan tame North Korea to win Games gold after shootout drama
-
NY attorney general tasked with investigating alleged Cornell gang rape
-
US posts weak job growth data in September
-
China widens military footprint with Laos air base
-
Ethiopia's conflict: the regional dimension
-
G7 talks as US pressures Europe over diesel stocks
-
Life expectancy almost back to pre-Covid levels, says WHO
-
Man City launch appeal against explosive financial ruling
CV Sciences Launches PlusHLTH.com, Expanding Its Consumer Platform Beyond Cannabinoids
New digital destination brings the Company's Health Intelligence approach to life, helping consumers better understand their needs, discover science-backed solutions, and navigate healthy aging.
SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "our", "us" or "we"), a consumer health company specializing in science-backed natural ingredients and products, today announced the launch of PlusHLTH.com, a new direct-to-consumer destination dedicated exclusively to the Company's growing +PlusHLTH™ product line.
The launch of PlusHLTH.com represents an important milestone in the Company's long-term strategy to expand beyond cannabinoids and establish +PlusHLTH™ as a leading brand focused on healthy aging, performance, and everyday health. The new site creates a distinct home for +PlusHLTH™, while PlusCBDOil.com remains focused on the Company's industry-leading hemp-derived CBD portfolio.
Built around CV Sciences' Health Intelligence approach, PlusHLTH.com is designed to be more than an e-commerce destination. The site brings together science-backed products and educational content to help consumers better understand their changing needs, explore targeted solutions, and make more informed decisions as they age.
"Our launch of PlusHLTH.com marks an exciting step in the evolution of CV Sciences," said Joseph Dowling, Chief Executive Officer of CV Sciences. "For more than a decade, we have earned the trust of consumers through our commitment to quality, scientific research, and product innovation with the PlusCBD brand. +PlusHLTH™ builds on that foundation by bringing the same commitment to a broader range of solutions designed to support healthy aging, active lifestyles, and everyday health."
"PlusHLTH.com gives +PlusHLTH™ its own distinct digital identity and creates a stronger connection with consumers," Dowling continued. "As the brand grows, the site gives us a place to introduce new products, provide meaningful education, and create an experience that evolves alongside our customers."
+PlusHLTH™ currently offers a growing range of non-cannabinoid nutritional products, including targeted dietary supplements in capsule and gummy formulations and Empowr, the Company's plant-based protein with creatine. The Company plans to continue expanding the line with new formulations and delivery formats designed to address evolving consumer needs.
PlusHLTH.com will serve as the primary digital home for +PlusHLTH™ products, education, new product introductions, and future innovation as CV Sciences continues to expand its presence in the broader health and nutrition market.
Consumers can explore the new website and learn more about +PlusHLTH™ by visiting www.PlusHLTH.com.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company focused on developing and commercializing science-backed natural products that support health and well-being. Through its trusted consumer brands, the Company offers a broad portfolio of premium hemp-derived CBD products, non-cannabinoid dietary supplements, and plant-based nutrition products designed to help consumers optimize their health at every stage of life.
The Company's +PlusCBD™ brand is among the leading hemp-extract brands in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic, and specialty products industry. +PlusCBD™ was the first hemp extract supplement brand to achieve self-affirmed Generally Recognized as Safe (GRAS) status and is supported by human clinical research and published scientific studies.
Under its +PlusHLTH™ brand, the Company offers a growing portfolio of science-backed non-cannabinoid wellness products, including dietary supplements and the Empowr plant-based protein with creatine. +PlusHLTH™ is focused on delivering innovative nutritional solutions that support healthy aging, active lifestyles, and everyday wellness.
CV Sciences also operates Cultured Foods™, a European producer of 100% plant-based food products, and Elevated Softgels™, a leading manufacturer of encapsulated softgels and tinctures serving the supplement and nutrition industries. Headquartered in San Diego, California, CV Sciences has operations in Colorado and Poland. Additional information is available at www.cvsciences.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's growth strategy, expansion of the +PlusHLTH™ brand, future product introductions, direct-to-consumer initiatives, and expected consumer demand. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are encouraged to review the Company's filings with the Securities and Exchange Commission for a discussion of these and other risk factors. The Company undertakes no obligation to update any forward-looking statements except as required by law.
CONTACT INFORMATION:
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire
A.Malone--AMWN